EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation

Guy Lalonde iD, Nikos Tsolakos, Tessa R Moir-Savitz iD, Alex M Easley, Charles L Gaworski, Michael J Oldham iD

Human & Experimental Toxicology · 2024

DOI: 10.1177/09603271241248631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human & Experimental Toxicology, 2024. Verfasst von Guy Lalonde und 5 weiteren Autor:innen. Beteiligte Einrichtung: Juul Labs, Inc., Washington, DC, USA. Hauptthemen laut MEDLINE: Electronic Nicotine Delivery Systems, Nicotine. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Juul Labs, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fresh Menthol 3% Nicotine (FM3) is a novel JUUL e-liquid formulation. Its potential toxicity and that of the corresponding base formulation relative to a filtered air (FA) control was studied in a subchronic inhalation study conducted in general accordance with OECD 413.

Methods

Aerosols generated with an intense puffing regime were administered to rats in a nose-only fashion at 1400 µg aerosol collected mass/L on a 6 hour/day basis for 90 days with a 42-day recovery. Exposure atmospheres met target criteria. Systemic exposure was confirmed by plasma measurement of nicotine.

Results

No test article-related mortality, clinical signs (other than reversible lower body weight gains in males), clinical pathology or gross findings were noted during this study. No microscopic lesions related to base formulation exposure were identified. Minimal microscopic lesions were observed in the FM3 6-hour exposure group. Microscopic lesions observed in the FM3 6-hour exposure group comprised only minimal laryngeal squamous metaplasia in one male and one female animal. No microscopic lesions related to FM3 exposure remained after the recovery period.

Conclusion

Exposure atmosphere characterization indicated that conditions were achieved to permit thorough assessment of test articles and results indicate a low order of toxicity for the FM3 Electronic nicotine delivery systems (ENDS) formulation and its base formulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Nicotine Delivery SystemsNicotineAnimalsMaleFemaleAdministration, InhalationToxicity Tests, SubchronicAerosolsMentholRats, Sprague-DawleyRatsInhalation Exposure

Stichwörter der Autor:innen

Inhalation toxicologyOECD 413base formulationelectronic nicotine delivery systemsratssubchronic

Substanzen

NicotineAerosolsMenthol

Autor:innen und Institutionen

  • Juul Labs, Inc., Washington, DC, USA.
  • Protavio Ltd, Attiki, Greece.
  • AmplifyBio, West Jefferson, OH, USA.
  • Kozmin Consulting LLC, Flat Rock, NC, USA.

ORCID-Profile: Guy Lalonde, Tessa R Moir-Savitz, Michael J Oldham

Förderung

  • Juul Labs, Inc.

Zitieren

APA

Lalonde, G., Tsolakos, N., Moir-Savitz, T. R., Easley, A. M., Gaworski, C. L., & Oldham, M. J. (2024). Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation. Human & Experimental Toxicology. https://doi.org/10.1177/09603271241248631

Vancouver

Lalonde G, Tsolakos N, Moir-Savitz TR, Easley AM, Gaworski CL, Oldham MJ. Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation. Human & Experimental Toxicology. 2024. doi:10.1177/09603271241248631

BibTeX
@article{Lalonde2024,
  author = {Lalonde, Guy and Tsolakos, Nikos and Moir-Savitz, Tessa R and Easley, Alex M and Gaworski, Charles L and Oldham, Michael J},
  title = {Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation},
  journal = {Human & Experimental Toxicology},
  year = {2024},
  doi = {10.1177/09603271241248631}
}
Kostenlos starten →